setting where TMS is used for several assays, as is the case in other laboratories (6 ), it makes economic sense to consolidate to one platform that can perform multiple assays without operator intervention.
Fetal DNA is present in plasma of pregnant women in amounts almost 1000-fold higher than the DNA present in intact fetal cells circulating in maternal peripheral blood (1, 2 ) . The clinical usefulness of fetal DNA from plasma for noninvasive prenatal diagnosis has been demonstrated recently through analysis of the fetal RhD status by PCR-based approaches (3) (4) (5) . We explored the possibility that not all of this fetal DNA is soluble and cell-free, but that part of it is still cell-associated.
Heparin blood samples of 25-30 mL were obtained after informed consent from 38 pregnant women attending the Prenatal Diagnostic Center at week 7-16 of gestation. Several weeks after blood withdrawal, chorionic villus sampling or amniocentesis was performed as planned at each patient's first visit. The protocol was approved by the Committee of Medical Ethics of the University Hospital 'Vrije Universiteit'. Blood samples were processed on the day of withdrawal and were centrifuged on a discontinuous Percoll gradient as described previously (6, 7 ) . In brief, after dilution of the heparin blood in Hanks' balanced salt solution; 1:2 dilution (Life Technologies), blood was layered on a 5-step Percoll density gradient consisting of 15 mL of 600 mL/L and 5 mL each of 550, 500, 450, and 400 mL/L Percoll in Hanks' balanced salt solution. After centrifugation for 25 min at 1000g at room temperature, plasma samples were removed from the upper part of the gradient, and cells with density 1.053-1.060 kg/L were removed for our study on circulating fetal trophoblast cells (7 ) . The plasma samples were centrifuged twice for 10 min at 500g in a microcentrifuge, and pellets were washed in phosphate-buffered saline. After the cells were stained with 4Ј,6-diamidine-2Ј-phenylindole dihydrochloride, we noticed the presence of intact nuclei by microscopic analysis of these samples (300 -400 cells/mL blood). Interestingly, the majority of these nuclei showed morphological features suggestive of apoptosis (a lobular appearance). When we used the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay (TUNEL) with the In Situ Cell Death Detection Kit (Roche Diagnostics), the majority of these cells (Ͼ95%) were labeled. In contrast, in control TUNEL assays using samples consisting of cells removed from the same gradient with density 1.053-1.060 kg/L, Ͻ1% of the cells were found to be in apoptosis.
Cells isolated from plasma were pretreated by proteinase K incubation (final concentration, 0.5 g/L) for 60 min at 55°C in PCR buffer and subjected to a nested X/Ychromosome-specific PCR assay followed by Southern blotting to assess the presence of fetal DNA. The PCR was performed as described previously (6 ) . All samples were positive for the X chromosome, indicating efficient isolation of DNA in all samples. The Y-chromosome-specific 254-bp end-product of the PCR assay was labeled with digoxigenin 11-dUTP and used as a probe for Southern blotting. Results of PCRs followed by blotting (Table 1) were compared with results of conventional karyotyping after chorionic villus sampling or amniocentesis in the same women (gold standard). PCR results of cells isolated from plasma of 31 pregnant women of 38 patients in total correlated with the gold standard (i.e., 81.6% correct). In two patients, PCR results were not interpretable. Three of 16 female samples were false positives, presumably because of contamination; at least one of these samples was negative in a subsequent assay. Two of 22 male samples were false negatives, probably because of the low amount of fetal DNA present in these very early pregnancy samples (all false-negative samples were obtained before 11 weeks of gestation). Lo et al. (3 ) described their RhD-PCR test as reliable at the beginning of the second trimester. When only samples taken at Ͼ11 weeks of gestation were included in our study (n ϭ 10 male fetuses), no false-negative results were observed.
Finally, using fluorescent DNA in situ hybridization L of CEP hybridization buffer (Vysis), and the target were co-denatured on a hot plate at 75°C for 2.5 min. Hybridizations were performed overnight in a moist chamber at 42°C. Slides were washed three times in 2ϫ standard saline citrate (SSC) containing 500 mL/L formamide (pH 7-8) and once in 2ϫ SSC (pH 7-7.5) for 10 min each at 45°C and once in 2ϫ SSC containing 1 g/L NP-40 for 5 min at 45°C. Following dehydration, cells were embedded in Vectashield (Vector), and photographs were made using a Fuji film Sensia II 400 on a Zeiss Axiophot microscope equipped with filters for fluorescence and a 100 W mercury arc lamp. In a pilot experiment, samples from nine pregnant women (gestational age, 7-13 weeks) were analyzed using this X/Y-FISH assay: one false-positive and no false-negative results were obtained (88% correct). A representative FISH result is shown in Fig. 1 . In five samples from women with male fetuses, X/Y cells were found in all slides, varying from 1 to 5 cells per slide (ϳ2000 cells per slide). In four samples from women with female fetuses, in only one sample, one single positive X/Y cell was found. The relative proportion of apoptotic fetal and maternal cells isolated from plasma were between 1:500 and 1:2000. These data indicate that part of the fetal DNA present in plasma of pregnant women circulates in the form of intact cells and can easily be obtained by centrifugation of the plasma samples. Moreover, despite being in the process of apoptosis, these cells are amenable to both FISH and PCR analysis (at least X-and Y-chromosome identification). If confirmed for other chromosomes, this approach will allow not only rapid noninvasive analysis of fetal DNA by 
10 ϩ 6 X X ϩ 31 13 ϩ 4 X Y Ϫ 32 9 XX ϩ 33 9 ϩ 2 X X ϩ 34 10 ϩ 1 ‫ء‬ * 35 10 ϩ 1 X X ϩ 36 8 ϩ 6 X X ϩ 37 16 ϩ 1 X X ϩ 38 9 ϩ 1 X X ϩ a ‫,ء‬ PCR result not interpretable (smear on blot), leading to a noninformative sample. Human plasma selenium is associated with three proteins: selenoprotein P (Se-P), glutathione peroxidase (isoform 3 of GSHPx), and albumin (1, 2 ) . Most of the methods used to study the distribution of plasma selenium among these proteins are based on gel filtration (3-6 ) or on affinity chromatography (2, (7) (8) (9) . Gel filtration is less sensitive, resolves less well, and has given higher results than affinity chromatography for GSHPx (7 ) . Affinity chromatography is time-consuming and unsuitable for routine analyses. The only direct method to determine plasma Se-P is a RIA (10, 11 ) . We developed an indirect determination of Se-P. After plasma albumin-globulin separation, the selenium content of the albumin fraction was measured and the selenium content of plasma Se-P was deduced from the total plasma selenium minus the sum of selenium coming from plasma albumin and GSHPx.
In a previous study, we showed that plasma selenium was significantly decreased in a group of institutionalized elderly women compared with a free-living group and a group of young adult women living in the same area (12 ). To investigate the etiology of the differences in selenium status among these groups, we studied plasma selenium distribution among the three protein compartments.
The three groups of nine women have been described elsewhere (12 ). Blood samples were collected in the fasting state.
Affinity chromatography on a tandem column system of heparin-Sepharose CL-6B (Pharmacia) and blue Sepharose CL-6B (Pharmacia) was performed for the separation of GSHPx, Se-P, and albumin in human plasma according to reported methods (2, 8 ) . To establish a correspondence between the activity and the selenium content of plasma GSHPx, GSHPx activity and selenium were measured in all unretained fractions because the unretained fraction from heparin-Sepharose and reactive blue columns correspond to the GSHPx fraction (7 ) .
Albumin and globulins were separated from one another by precipitation with ammonium sulfate at halfsaturation at neutral pH. Equal volumes of plasma and saturated ammonium sulfate solution were mixed and left for 30 min in an ice bath. After refrigerated centrifugation at 2600g for 15 min, the supernatant was removed. To the precipitate, we added 1 mL of deionized water and 1 mL of saturated ammonium sulfate solution. The precipitate was suspended by shaking, and the tube was placed in an ice bath for 30 min and then centrifuged. The supernatant was removed, combined with the first supernatant, and designated the albumin fraction. The final precipitate was considered the globulin fraction.
Plasma albumin and albumin in the supernatant were measured by immunoprecipitation (BNA-Behring). For the plasma samples, globulin fractions, and albumin fractions, selenium was determined by gas chromatography-mass spectrometry (13 ). For plasma and column fractions, GSHPx was assayed using a modified Gü nzler method (14 ) .
All values were calculated as the mean Ϯ SD. Significance was set as P Ͻ0.05.
Affinity chromatography was performed on two human plasma samples for estimating the percentage of selenium associated with GSHPx in plasma. In the sum of unretained fractions, GSHPx activities were 274 and 296 U/L, respectively, for the two samples, and selenium concentrations were 12.7 and 15.4 g/L, respectively. The deduced plasma GSHPx activity per unit of selenium was 20 U/g selenium. This value was further used to convert the measured GSHPx activity to the amount of selenium GSHPx of the other human samples. GSHPx activity recovery was estimated to be satisfactory because in the initial plasma samples, the GSHPx activities were 290 and 303 U/L, respectively.
Albumin recovery was estimated by the albumin measurement in plasma and in the albumin fraction; the recovery for 23 samples was 92.7% Ϯ 16.7%. Selenium
Clinical Chemistry
46, No. 5, 2000
